Neurocrine Plans to Lay Off Half Its Staff
Wednesday, May 6, 2009
Neurocrine Biosciences, maker of experimental drugs for treating neurological and endocrine disorders, said May 6 it would cut its 120-person staff in half to conserve cash as it focuses on moving its midstage clinical programs into final Phase 3 trials...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
- 52 weekly issues
- Subscriber-only digital content every business day, plus full access to SDBJ.com archives
- Book of Lists — the most comprehensive business resource in San Diego
- San Diego 500 — influential business leaders you need to know